This guidance recommends approaches that sponsors of clinical trials intended to support a new drug application or a biologics license application can take to increase enrollment of a representative population in their clinical trials.
Similar Posts
FDA In Brief: FDA seeks input on development and evaluation of abuse-deterrent formulations of central nervous system stimulants
FDA seeks input on development and evaluation of abuse-deterrent formulations of central nervous system stimulantsSecret Miracle Honey Extra Strength may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Secret Miracle Honey Extra Strength, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Apotex Inc. – 05/09/2025
Apotex Inc. – 05/09/2025. Country: Canada. Record Type: 483CDER Staff Member Shares Her Experience in a Breast Cancer Clinical Trial
She was overwhelmed, but she felt the trial was her best chance for a successful outcome.Correction Alert: Olympus Updates Use Instructions for Ligating Device
Olympus ligation loops may be unable to release or detach as expected during use and may become unintentionally anchored around patient anatomy
July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement – 07/18/2025
July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement